Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2028
SKU ID :DEL-13519008 | Published Date: 01-Jan-2019 | No. of pages: 100Description
TOC
1. Report Introduction
2. Febrile Neutropenia Market Overview at a Glance
2.1. Market Share Distribution of Febrile Neutropenia in 2016
2.2. Market Share Distribution of Febrile Neutropenia in 2028
3. Disease Background and Overview: Febrile Neutropenia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Febrile Neutropenia in 7MM
4.3. Total Prevalent Patient Population of Febrile Neutropenia in 7MM – By Countries
5. Epidemiology of Febrile Neutropenia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.1.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.1.4. Sex- Specific Cases of the Febrile Neutropenia *
5.1.5. Diagnosed Cases of the Febrile Neutropenia
5.1.6. Treatable Cases of the Febrile Neutropenia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.4.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.4.4. Sex- Specific Cases of the Febrile Neutropenia *
5.4.5. Diagnosed Cases of the Febrile Neutropenia
5.4.6. Treatable Cases of the Febrile Neutropenia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.5.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.5.4. Sex- Specific Cases of the Febrile Neutropenia *
5.5.5. Diagnosed Cases of the Febrile Neutropenia
5.5.6. Treatable Cases of the Febrile Neutropenia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.6.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.6.4. Sex- Specific Cases of the Febrile Neutropenia *
5.6.5. Diagnosed Cases of the Febrile Neutropenia
5.6.6. Treatable Cases of the Febrile Neutropenia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.7.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.7.4. Sex- Specific Cases of the Febrile Neutropenia *
5.7.5. Diagnosed Cases of the Febrile Neutropenia
5.7.6. Treatable Cases of the Febrile Neutropenia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.8.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.8.4. Sex- Specific Cases of the Febrile Neutropenia *
5.8.5. Diagnosed Cases of the Febrile Neutropenia
5.8.6. Treatable Cases of the Febrile Neutropenia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.9.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.9.4. Sex- Specific Cases of the Febrile Neutropenia *
5.9.5. Diagnosed Cases of the Febrile Neutropenia
5.9.6. Treatable Cases of the Febrile Neutropenia
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Febrile Neutropenia
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Febrile Neutropenia
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Febrile Neutropenia : 7MM Market Analysis
12.1. 7MM Market Size of Febrile Neutropenia
12.2. 7MM Percentage Share of drugs marketed for Febrile Neutropenia
12.3. 7MM Market Sales of Febrile Neutropenia by Products
13. Febrile Neutropenia : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Febrile Neutropenia in United States
13.1.2. Percentage Share of drugs marketed for Febrile Neutropenia in United States
13.1.3. Market Sales of Febrile Neutropenia by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Febrile Neutropenia in Germany
13.2.1.2. Percentage Share of drugs marketed for Febrile Neutropenia in Germany
13.2.1.3. Market Sales of Febrile Neutropenia by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Febrile Neutropenia in France
13.2.2.2. Percentage Share of drugs marketed for Febrile Neutropenia in France
13.2.2.3. Market Sales of Febrile Neutropenia by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Febrile Neutropenia in Italy
13.2.3.2. Percentage Share of drugs marketed for Febrile Neutropenia in Italy
13.2.3.3. Market Sales of Febrile Neutropenia by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Febrile Neutropenia in Spain
13.2.4.2. Percentage Share of drugs marketed for Febrile Neutropenia in Spain
13.2.4.3. Market Sales of Febrile Neutropenia by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Febrile Neutropenia in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Febrile Neutropenia in United Kingdom
13.2.5.3. Market Sales of Febrile Neutropenia by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Febrile Neutropenia in Japan
13.3.2. Percentage Share of drugs marketed for Febrile Neutropenia in Japan
13.3.3. Market Sales of Febrile Neutropenia by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Indication Specific
Tables & Figures
Table 1: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM
Table 2: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Febrile Neutropenia in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Febrile Neutropenia in United States (2016-2028)
Table 5: Sex- Specific Cases of the Febrile Neutropenia in United States (2016-2028)
Table 6: Diagnosed Cases of the Febrile Neutropenia in United States (2016-2028)
Table 7: Treatable Cases of the Febrile Neutropenia in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Febrile Neutropenia in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Febrile Neutropenia in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Febrile Neutropenia in Germany (2016-2028)
Table 11: Diagnosed Cases of the Febrile Neutropenia in Germany (2016-2028)
Table 12: Treatable Cases of the Febrile Neutropenia in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Febrile Neutropenia in France (2016-2028)
Table 14: Sub-Type Specific cases of the Febrile Neutropenia in France (2016-2028)
Table 15: Sex- Specific Cases of the Febrile Neutropenia in France (2016-2028)
Table 16: Diagnosed Cases of the Febrile Neutropenia in France (2016-2028)
Table 17: Treatable Cases of the Febrile Neutropenia in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Febrile Neutropenia in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Febrile Neutropenia in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Febrile Neutropenia in Italy (2016-2028)
Table 21: Diagnosed Cases of the Febrile Neutropenia in Italy (2016-2028)
Table 22: Treatable Cases of the Febrile Neutropenia in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Febrile Neutropenia in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Febrile Neutropenia in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Febrile Neutropenia in Spain (2016-2028)
Table 26: Diagnosed Cases of the Febrile Neutropenia in Spain (2016-2028)
Table 27: Treatable Cases of the Febrile Neutropenia in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Febrile Neutropenia in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Febrile Neutropenia in UK (2016-2028)
Table 30: Sex- Specific Cases of the Febrile Neutropenia in UK (2016-2028)
Table 31: Diagnosed Cases of the Febrile Neutropenia in UK (2016-2028)
Table 32: Treatable Cases of the Febrile Neutropenia in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Febrile Neutropenia in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Febrile Neutropenia in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Febrile Neutropenia in Japan (2016-2028)
Table 36: Diagnosed Cases of the Febrile Neutropenia in Japan (2016-2028)
Table 37: Treatable Cases of the Febrile Neutropenia in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 42:7MM- Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 45: United States-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 48: Germany-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 51: France-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 54: Italy-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 57: Spain-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 60:UK-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Table 63: Japan-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM
Figure 2: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Febrile Neutropenia in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Febrile Neutropenia in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Febrile Neutropenia in United States (2016-2028)
Figure 6: Diagnosed Cases of the Febrile Neutropenia in United States (2016-2028)
Figure 7: Treatable Cases of the Febrile Neutropenia in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Febrile Neutropenia in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Febrile Neutropenia in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Febrile Neutropenia in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Febrile Neutropenia in Germany (2016-2028)
Figure 12: Treatable Cases of the Febrile Neutropenia in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Febrile Neutropenia in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Febrile Neutropenia in France (2016-2028)
Figure 15: Sex- Specific Cases of the Febrile Neutropenia in France (2016-2028)
Figure 16: Diagnosed Cases of the Febrile Neutropenia in France (2016-2028)
Figure 17: Treatable Cases of the Febrile Neutropenia in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Febrile Neutropenia in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Febrile Neutropenia in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Febrile Neutropenia in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Febrile Neutropenia in Italy (2016-2028)
Figure 22: Treatable Cases of the Febrile Neutropenia in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Febrile Neutropenia in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Febrile Neutropenia in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Febrile Neutropenia in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Febrile Neutropenia in Spain (2016-2028)
Figure 27: Treatable Cases of the Febrile Neutropenia in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Febrile Neutropenia in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Febrile Neutropenia in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Febrile Neutropenia in UK (2016-2028)
Figure 31: Diagnosed Cases of the Febrile Neutropenia in UK (2016-2028)
Figure 32: Treatable Cases of the Febrile Neutropenia in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Febrile Neutropenia in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Febrile Neutropenia in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Febrile Neutropenia in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Febrile Neutropenia in Japan (2016-2028)
Figure 37: Treatable Cases of the Febrile Neutropenia in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 42:7MM- Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 45: United States-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 48: Germany-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 51: France-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 54: Italy-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 57: Spain-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 60:UK-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Febrile Neutropenia in USD MM (2016-2028)
Figure 63: Japan-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2028)
Companies
- PRICE
-
$6250$18750